Serina Therapeutics Stock Price, News & Analysis

Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company, has announced its 2025 Annual Stockholders Meeting will be held on November 7, 2025. The specific time and location will be detailed in the company's definitive proxy statement to be filed with the SEC.

Due to the meeting date change of more than 30 days from the 2024 annual meeting anniversary, stockholder proposals under Rule 14a-8 must be submitted by 5:00 p.m. (Central Time) on August 15, 2025. For stockholder proposals and director nominations under the company's bylaws, submissions must be received between July 10, 2025, and August 9, 2025 at the company's Huntsville, Alabama headquarters.

Serina Therapeutics (NYSE American: SER) announced its CEO Steve Ledger will present at a FORCE Family Office investor webinar on June 26, 2025, at 12:00 p.m. ET. The presentation, titled "New Drug Optimization Platform to Transform Parkinson's Care," will focus on the company's drug candidate SER-252, a polymer conjugate of apomorphine designed to provide continuous dopaminergic stimulation for Parkinson's disease treatment.

The webinar will highlight the company's POZ Platform™ technology and its potential to improve safety, duration, and tolerability of Parkinson's treatments. The event will include a Q&A session hosted by FORCE Family Office CEO Steve Saltzstein.

Serina Therapeutics (NYSE: SER) announces that its strategic partner and largest shareholder, Juvenescence Ltd., has secured $76 million in the first tranche of its targeted $150 million Series B financing round. Additionally, Juvenescence has formed a strategic partnership with M42, a tech-enabled health company based in Abu Dhabi. The partnership includes plans to establish a drug development hub in Abu Dhabi, combining AI-enabled drug discovery with advanced data and clinical infrastructure. Serina Therapeutics, which is developing the POZ Platform™ drug optimization technology, views this development as beneficial due to Juvenescence's role in providing strategic guidance and capital support. The collaboration between Juvenescence and M42 aims to accelerate the development of therapies targeting age-related diseases and extending healthspan.

Serina Therapeutics (NYSE: SER) announces that its strategic partner and largest shareholder, Juvenescence Ltd., has secured $150 million in Series B funding led by M42, a tech-enabled health company from Abu Dhabi. The partnership includes plans to establish a drug development hub in Abu Dhabi, combining AI-enabled drug discovery with advanced data and clinical infrastructure. Juvenescence's investment will support the development of innovative therapies targeting age-related diseases and extending healthspan. Serina Therapeutics, which is developing its POZ Platform drug optimization technology, benefits from Juvenescence's strategic guidance and capital support in advancing their clinical programs.

Serina Therapeutics (NYSE: SER) has announced that CEO Steven A. Ledger will present at an upcoming Tribe Public Webinar titled 'Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?' scheduled for June 11, 2025, at 8:30 AM PT/11:30 AM ET. The presentation comes at a significant time as the biotech sector enters its fifth year of a bear market, with approximately 25% of 700-800 publicly traded US biotech companies showing negative enterprise values. Serina, a clinical-stage biotech company, is developing its proprietary POZ Platform for drug optimization. The event will be hosted by Tribe Public's Managing Member John F. Heerdink, Jr., and interested participants can register for free at Smartest-Bet.TribePublic.com.

Serina Therapeutics (NYSE: SER) has appointed Dr. Stephen Brannan to its Board of Directors. Dr. Brannan brings over 30 years of experience in neuroscience and neuropsychiatry drug development. He most recently served as Chief Medical Officer at Karuna Therapeutics, where he led the clinical development of KarXT, the first new schizophrenia treatment mechanism in over 30 years, which contributed to Karuna's $14 billion acquisition by Bristol Myers Squibb in 2024.

Dr. Brannan's extensive experience includes senior leadership roles at Takeda, Novartis, Cyberonics, and Eli Lilly, where he directed clinical programs in various CNS conditions. He will support Serina's strategic development of long-acting CNS therapeutics using their proprietary POZ Platform™ technology. The company also announced the departure of Remy Gross from its Board, who will continue supporting the team in a consulting role.

Serina Therapeutics (NYSE: SER), a clinical-stage biotech company developing SER-252 for advanced Parkinson's disease, has granted stock options to two new non-executive employees. The grants, totaling 15,000 shares of common stock, were made on March 20, 2025, with an exercise price matching the closing stock price on that date.

The Option Grants, approved by Serina's Compensation Committee under the 2024 Inducement Equity Plan, will vest over four years: 25% after the first year and the remaining 75% in three equal annual installments, subject to continued employment. These grants were made as employment inducements in compliance with NYSE American's Company Guide Section 711(a).

Serina's proprietary POZ Platform™ technology enables drug optimization for their lead candidate.

Serina Therapeutics (NYSE: SER) reported Q1 2025 financial results and business updates. The company secured $15 million in equity financing, including $10M from JuvVentures and $5M from board directors and investors. Key highlights include preparations for Phase 1b trial of SER-252 for advanced Parkinson's disease, scheduled for Q4 2025. The company reported a net loss of $4.8 million ($0.49 per share) compared to $15.0 million loss in Q1 2024. Operating expenses increased to $5.9M from $2.3M year-over-year. Cash position stands at $4.3M as of March 31, 2025, with runway through Q3 2025. The company also appointed two new board members and presented promising data on their POZ-lipid technology showing no immune response in contrast to PEG-lipid standards.

Serina Therapeutics, a clinical-stage biotech company listed on NYSE American under ticker SER, has announced its participation in the upcoming JonesResearch Virtual CNS Day. The company, known for developing the proprietary POZ Platform™ drug optimization technology, will be represented by CEO Steve Ledger in a fireside chat presentation.

The virtual event is scheduled for April 29, 2025, at 12:00 p.m. EDT. Registered attendees can access the live webcast through a provided Zoom link. For those unable to attend the live session, an archived replay will remain available on-demand for 90 days after the event.